Xtant Medical (XTNT) to Release Quarterly Earnings on Tuesday

Key Points

• Xtant Medical (XTNT) will release its quarterly earnings on August 12th, with analysts anticipating a loss of $0.02 per share and revenues of approximately $31.35 million.
• The stock of Xtant Medical has seen an increase of 3.8%, trading at $0.57 during mid-day, with a market capitalization of $79.72 million.
• Xtant Medical specializes in regenerative medicine products and medical devices aimed at orthopedic and neurological procedures.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Xtant Medical to post earnings of ($0.02) per share and revenue of $31.35 million for the quarter.

Xtant Medical Stock Up 3.8%

Shares of NYSEAMERICAN XTNT traded up $0.02 during mid-day trading on Wednesday, reaching $0.57. 29,145 shares of the company's stock were exchanged, compared to its average volume of 126,765. The firm has a market capitalization of $79.72 million, a price-to-earnings ratio of -6.36 and a beta of -0.21. The business has a fifty day simple moving average of $0.64 and a 200 day simple moving average of $0.55. Xtant Medical has a twelve month low of $0.33 and a twelve month high of $0.78. The company has a current ratio of 2.34, a quick ratio of 1.03 and a debt-to-equity ratio of 0.51.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.